Welcome to our dedicated page for Affimed news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed stock.
Affimed N.V. (AFMD) has been a Nasdaq-listed, clinical-stage immuno-oncology company focused on innate cell engagers (ICE®) generated on its proprietary ROCK® platform. Company news has highlighted how these ICE® molecules are being developed to recognize and kill a range of hematologic and solid tumors by engaging innate immune cells.
News coverage for AFMD includes detailed clinical updates on key ICE® programs such as AFM24, AFM28 and acimtamig (AFM13). Releases describe AFM24 as a tetravalent, bispecific ICE® targeting CD16A and EGFR, with data in advanced or metastatic non-small cell lung cancer, including combinations with atezolizumab. For AFM28, Affimed has reported early Phase 1 results in relapsed/refractory acute myeloid leukemia, including composite complete remission rates and safety findings. Additional news has covered acimtamig in combination with AlloNK® (AB-101) in classical Hodgkin lymphoma, with abstracts accepted for major oncology meetings.
Another important category of AFMD news relates to corporate and listing developments. In May 2025, Affimed announced that it had filed for insolvency proceedings in Mannheim, Germany, citing overindebtedness and liquidity concerns. Shortly thereafter, the company disclosed that Nasdaq staff would suspend trading of its common shares and proceed with a delisting process, culminating in a Form 25 filing to remove its common stock from Nasdaq listing and registration.
On this news page, readers can review historical press releases on AFMD’s clinical trial data, conference presentations, investor webcasts, and regulatory and listing updates. For those tracking the company’s ICE® pipeline and its insolvency and delisting process, this archive offers a centralized view of how Affimed’s scientific, clinical, and corporate story has evolved over time.
Affimed has announced the successful completion of the first dose cohort in a Phase 1/2a clinical trial for AFM24, a novel bispecific innate cell engager targeting EGFR-expressing malignancies. No dose-limiting toxicities were observed, allowing progression to the second dose cohort. While efficacy was not expected at this stage, the trial aims to gather data on the safety and potential effectiveness of AFM24 as a treatment option. The company emphasizes that AFM24 could provide a new mechanism of action that utilizes innate immunity to combat cancer.
Heidelberg, Germany, June 16, 2020 – Affimed N.V. (Nasdaq: AFMD) will release its first quarter 2020 financial results on June 23, 2020, at 8:30 a.m. EDT, followed by a conference call. Investors can join via phone or webcast, with details provided in the PR. Additionally, CEO Dr. Adi Hoess will participate in a fireside chat at the BMO Healthcare Conference on the same day at 1:30 p.m. EDT. Affimed focuses on immuno-oncology, developing therapies for various cancers, including studies for AFM13 and AFM24.
Affimed N.V. (Nasdaq: AFMD) announced the appointment of Angus Smith as the new Chief Financial Officer, effective July 13, 2020. This appointment completes the company's leadership team. Smith brings extensive biopharmaceutical experience, having previously served as CFO at Rockwell Medical. His expertise in financial management and US capital markets is expected to enhance Affimed's strategic position during its upcoming growth phase. The company develops innovative cancer treatments using its ROCK® platform and is advancing clinical studies for therapies targeting hematologic and solid tumors.
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, will have its CEO, Dr. Adi Hoess, present at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 8:00 a.m. Eastern Time. The presentation will be available via a live webcast on Affimed’s website and accessible for 30 days post-event. Affimed focuses on innovative therapies to empower patients against cancer, currently developing AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma, and AFM24 for advanced EGFR-expressing solid tumors. For further details, visit www.affimed.com.
Affimed N.V. (Nasdaq: AFMD) announced participation in the AACR Virtual Annual Meeting II on June 22-24, 2020, with two studies on innate cell engagers from its ROCK® platform. Researchers from Affimed will present data on AFM24, a bispecific EGFR/CD16A Innate Cell Engager, and RO7297089, an anti-BCMA/CD16a antibody for multiple myeloma. A live teleconference will be held on May 15, 2020, at 8 am Eastern to discuss the abstracts and updates. Affimed continues to advance its clinical programs targeting cancer treatment.
Summary not available.